（以下无正文） （本页无正文，为《重庆新铝时代科技股份有限公司董事会关于拟购买资产不存 在关联方非经营性资金占用问题的说明》之盖章页） 重庆新铝时代科技股份有限公司董事会 关于拟购买资产不存在关联方非经营性资金占用问题的说明 重庆新铝时代科技股份有限公司（以下简称"上市公司"）拟通过发行股份 及支付现金的方式，购买陈旺等19名交易对手方合计持有的东莞市宏联电子有限 公司（以下简称"标的公司"）100%股权并募集配套资金（以下简称"本次交 易"）。 经核查，截至本说明出具之日，标的公司不存在被其股东及其关联方非经营 性占用资金事项。本次交易完成后，标的公司将成为上市公司的全资子公司，将 遵守上市公司关于防止关联方资金占用的相关制度，防止资金占用情形的发生。 特此说明。 重庆新铝时代科技股份有限公司 董事会 ...

Core Viewpoint - The article highlights serious financial misconduct at Weikang Pharmaceutical, including the misuse of company funds by its actual controller, Liu Zhongliang, and the subsequent impact on the company's financial performance and project timelines [3][4][6]. Financial Misconduct - Liu Zhongliang has occupied company funds totaling 157 million yuan, including 54 million yuan of raised funds, under the guise of paying for engineering equipment [1][4]. - The funds were ultimately transferred to personal accounts controlled by Liu Zhongliang, constituting non-operational fund occupation [3][4]. - The balances of fund occupation by the actual controller from 2020 to mid-2023 were 78.12 million yuan, 89.51 million yuan, 147.28 million yuan, and 151.22 million yuan, representing 5.64%, 6.35%, 10.43%, and 10.24% of net assets respectively [3][4]. Regulatory Actions - The Zhejiang Securities Regulatory Bureau has ordered Weikang Pharmaceutical to rectify the situation, issuing a warning and imposing a fine of 5 million yuan on the company and 7 million yuan on Liu Zhongliang [4][6]. Project Delays - Weikang Pharmaceutical's initial fundraising projects have faced multiple delays, with the first phase of the health industry park originally scheduled for completion in December 2020, now pushed back multiple times to 2025 [6][7]. - The marketing center project has also seen significant delays, with no new investments reported for 2023 and 2024 [7][8]. Financial Performance - The company's financial performance has deteriorated significantly since its IPO, with net profit dropping from 96 million yuan in 2021 to a loss of 147 million yuan in 2024 [9][10]. - Revenue has also declined from 633 million yuan in 2021 to 351 million yuan in 2024, contrasting sharply with pre-IPO growth [9][10]. Dividend Payments - Despite the losses, Weikang Pharmaceutical has continued to distribute dividends, with cash dividends of 35.51 million yuan in 2023 and 19.89 million yuan in 2024, even as the actual controller holds nearly 70% of the company's shares [11].

Core Viewpoint - The company, Changyuan Technology Group Co., Ltd., is under scrutiny from the Shanghai Stock Exchange regarding its 2024 annual report due to issues related to non-operating fund occupation by related parties, leading to significant internal control deficiencies and accounting errors [1][2][3]. Group 1: Related Party Fund Occupation - The company’s chairman, Wu Qiquan, is linked to Zhuhai Yuntaili Holdings Co., Ltd., which has been identified as occupying company funds through third parties [1][2]. - The annual audit revealed that the auditors could not obtain sufficient evidence to identify all related parties, resulting in a qualified opinion on the financial statements [1][3]. - The company has acknowledged the need to correct accounting errors related to non-operating fund occupation in its financial reports for 2023 and 2024 [1][3]. Group 2: Supplier Information and Financial Data - The company identified seven suppliers involved in fund occupation, detailing their establishment dates, major financial data, and actual controllers [2][3][4]. - For example, Zhuhai Chengbangda has total assets of 261.73 million yuan and a net profit of 5.5 million yuan as of December 31, 2024 [3][4]. - The company has initiated self-inspections and requested confirmations from these suppliers regarding their actual controllers and any potential fund occupation [4][5]. Group 3: Internal Control Deficiencies - The company has recognized significant internal control deficiencies in its fund payment approval and related party transaction processes [1][2][3]. - Contracts and payments related to the identified suppliers were executed without proper authorization, leading to difficulties in detecting fund occupation [1][2][3]. - The company plans to implement corrective measures and hold responsible personnel accountable for these deficiencies [2][3][5]. Group 4: Financial Adjustments and Reporting - The company has made retrospective adjustments to its financial statements for the years 2023 and 2024 to reflect the impact of the identified accounting errors [1][2][3]. - The adjustments include changes to monetary funds, other receivables, and credit impairment losses [1][2][3]. - The company has committed to adhering to accounting standards and ensuring timely disclosures of any further adjustments needed [1][2][3].

Core Viewpoint - The credit rating of Dongfang Shifang Driving School Co., Ltd. has been downgraded from B to CCC, with a negative outlook due to significant financial challenges and operational issues [1][7]. Financial Performance - The company reported a decline in main business income in 2024, attributed to factors such as consumer downgrade and insufficient student enrollment, resulting in a revenue decrease of 375 million yuan compared to 2023 [1]. - The company recognized asset impairment losses and credit impairment losses on its subsidiaries due to underperformance [1]. Audit Findings - The audit report from Beijing Dehao International Accounting Firm raised concerns about the recoverability of receivables from related parties, including: - 302.49 million yuan receivable from Beijing Qianzhong Fantasy Technology Co., Ltd. with a bad debt provision of 30.25 million yuan, related to the purchase of 3,179 VR simulators [2]. - 49.86 million yuan receivable from Beijing Tonglong Automobile Sales Co., Ltd. with a bad debt provision of 15.73 million yuan, related to incomplete delivery of AI training systems [3]. - 35 million yuan receivable from the controlling shareholder, with a bad debt provision of 3.5 million yuan, related to non-operational fund occupation [4]. Internal Control Issues - The internal control audit report indicated significant deficiencies in managing and recovering funds from related parties, with unresolved issues regarding the delivery of VR simulators and AI systems [4][5]. Regulatory Actions - The company received a corrective order from the China Securities Regulatory Commission, requiring the recovery of 387 million yuan in occupied funds within six months, failing which trading suspension and potential delisting could occur [6]. - As of June 19, 2025, no funds had been recovered, leading to a trading suspension effective June 20, 2025 [6]. Credit Rating Status - The company maintains a credit rating of CCC, with a negative outlook, reflecting ongoing financial distress and operational challenges [7].

Core Viewpoint - Weikang Pharmaceutical faces administrative penalties from the Zhejiang Securities Regulatory Bureau for information disclosure violations, including non-disclosure of related party non-operating fund occupation and inaccuracies in convertible bond prospectus [1][2][5] Group 1: Administrative Penalties - The Zhejiang Securities Regulatory Bureau plans to impose a total fine exceeding 14 million yuan on Weikang Pharmaceutical and its responsible individuals, including a 5 million yuan fine on the company and a 7 million yuan fine on its actual controller Liu Zhongliang [1][5] - Liu Zhongliang, who served as the chairman from March 2015 until May 2024, has retired and is no longer involved in the company [1][2] Group 2: Fund Misappropriation - Liu Zhongliang directed Weikang Pharmaceutical to transfer funds under the guise of paying for engineering equipment, which were ultimately transferred to his personal account, constituting non-operating fund occupation [2][3] - From 2018 to 2020, Liu Zhongliang borrowed 56.29 million yuan from the company to support a friend's new drug development, which was used for various personal and business expenses [2][3] Group 3: Financial Performance - Weikang Pharmaceutical's net profit has declined since its IPO in 2020, with losses reported in 2023 and the first quarter of 2025, showing a significant drop in revenue and profitability [6][7] - The company's gross margin has decreased from 72.41% in 2020 to 50.39% in 2023, attributed to a decline in high-margin prescription drug sales and increased costs [7] Group 4: Future Outlook - Liu Zhongliang expressed optimism about the company's future, focusing on the development and production of traditional Chinese medicine products, believing that difficulties are temporary and new growth will emerge in two to three years [7]

Core Viewpoint - ST Changyuan has disclosed its response to the Shanghai Stock Exchange's inquiry letter, addressing only two out of five major issues, while deferring responses on significant matters such as non-operating fund occupation by related parties, operating performance, and audit opinions due to the complexity of the issues involved [1][2][3]. Group 1: Financial Performance - In 2024, ST Changyuan reported a revenue of 7.874 billion yuan, a year-on-year decrease of 7.22%, and a net loss attributable to shareholders of 978 million yuan, marking a shift from profit to loss primarily due to a significant decline in the profitability of its main business and large goodwill impairment [2][3]. - The company’s accounts receivable at the end of the reporting period amounted to 3.515 billion yuan, with a provision for bad debts of 570 million yuan, including 233 million yuan for specific accounts [4]. Group 2: Related Party Transactions - The chairman of ST Changyuan, Wu Qiquan, controls Zhuhai Yuntaili Holdings Development Co., Ltd., which has occupied company funds through third parties, with balances of 294 million yuan and 264 million yuan at the end of 2023 and 2024, respectively [2][3]. Group 3: Audit Opinions - Due to the non-operating fund occupation by related parties, the financial report for 2024 received a qualified audit opinion, and the internal control report received a negative opinion [3]. Group 4: Accounts Receivable Financing - The accounts receivable financing balance at the end of 2024 was 492 million yuan, a year-on-year increase of 117.51%, primarily due to accounts receivable notes [4]. - The company reported a prepayment balance of 307 million yuan at the end of 2024, a year-on-year increase of 141.16%, mainly due to new prepayments for materials related to renewable energy projects [4][5].

Core Viewpoint - The report details a special on-site inspection conducted by Minsheng Securities regarding non-operating fund occupation by related parties of Tianli Lithium Energy Group, highlighting significant financial transactions and corrective measures taken by the company [1][2][8]. Group 1: Inspection Overview - Tianli Lithium Energy has experienced a total of 97 million yuan in fund occupation since 2024, primarily involving prepayments for lithium ore and transactions with related companies [1][2]. - Specific transactions include a prepayment of 58 million yuan to Aba Gaoyuan Lithium Battery Materials Co., with subsequent fund transfers leading to an occupation of 36 million yuan [1][2]. - The company also made a prepayment of 40 million yuan to Pingdingshan Xinkuo for battery-grade lithium carbonate, which resulted in a similar fund occupation situation [5][6]. Group 2: Rectification Measures - The company has implemented corrective actions, including reprimanding management and financial personnel, and adjusting their positions due to failure to identify fund usage risks [6][7]. - A written commitment from the controlling shareholder, Wang Ruiqing, has been obtained to prevent future fund occupation incidents, along with a promise to pay 645,400 yuan in occupation fees [5][6]. - The company plans to enhance internal audit functions and compliance awareness to prevent recurrence of such issues [6][7]. Group 3: Future Actions - Minsheng Securities will continue to monitor the situation and ensure compliance with relevant regulations and internal controls regarding related transactions and fund management [8]. - The company is expected to conduct training on compliance and governance to improve awareness of operational norms and risk management [6][8].

Core Viewpoint - YunChuang Data is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to significant financial restatements and potential delisting risks [1][4][15]. Financial Performance - In the first quarter of 2025, YunChuang Data reported a dramatic revenue decline of nearly 80%, with revenue falling below 9 million yuan, a fraction of the previous year's figures [6]. - The company revised its 2024 financial results, reducing reported revenue by 212 million yuan to 50 million yuan, and net profit by 65 million yuan to -174 million yuan [4][11]. - The company’s revenue for 2024 was initially reported at 262 million yuan, with a net loss of 109 million yuan [4]. Audit Findings - The auditing firm issued an "unable to express an opinion" report on YunChuang Data's 2024 financial statements due to several unresolved issues, including the CSRC's investigation and unverified major financial adjustments [7]. - Significant concerns were raised regarding the company's receivables from its controlling shareholder, amounting to 535 million yuan, indicating potential non-operational fund occupation [7][11]. Financial Irregularities - YunChuang Data is suspected of financial fraud, including the misuse of raised funds, with over 177 million yuan improperly used from the fundraising account [11]. - The company has shown a pattern of declining revenues over two consecutive years while maintaining stable accounts receivable, raising red flags about the authenticity of its financial reporting [9]. Asset Management - The company reported a substantial decrease in construction in progress from 230 million yuan to 37 million yuan within a year, which is inconsistent with its operational model [10]. - By the end of 2024, YunChuang Data's inventory dropped to 33 million yuan, a decrease of 83.91% from the previous year, alongside significant reductions in fixed and intangible assets [13]. Regulatory Implications - If found guilty of continuous false reporting over three years, YunChuang Data could face mandatory delisting under the North Exchange Stock Listing Rules [15][16]. - The adjustments made to the 2024 financials align with thresholds that could trigger severe penalties, including potential delisting due to the magnitude of the financial misstatements [16].

3月24日，香雪制药（300147.SZ）公告称，公司及相关当事人收到中国证监会广东监管局的《行政 处罚事先告知书》。香雪制药及王永辉、卢锋、陈炳华、黄滨、徐力、郝世明等人拟被罚合计2075万 元，其中王永辉违法情节严重，被采取5年证券市场禁入措施。 同日，香雪制药还发布了另外一份公告称，根据《深圳证券交易所创业板股票上市规则》第9.4条 规定，公司股票交易将被实施其他风险警示。公司股票自2025年3月25日（星期二）被实施其他风险警 示，股票简称由"香雪制药"变更为"ST香雪"。 公告显示，2019年12月，香雪制药位于广州生物岛上5栋别墅被相关政府部门拆除，香雪制药未按 规定确认拆除别墅产生的在建工程损失，导致2019年年度报告虚增利润5383.25万元，占当期披露利润 总额的45.98%，2019年年度报告存在虚假记载。 此外，2016年至2020年，香雪制药以购买信托理财、中药材合作经营等名义支出款项，并最终划转 至控股股东广州市昆仑投资有限公司等关联方，用于关联方偿还借款、收购股权等。2018年至2020年， 香雪制药代关联方广州香岚健康产业有限公司支付香岚官洲酒店工程款。 香雪制药及相关人员拟被罚 ...